Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors.

Bendell JC, Patel MR, Yoshida K, Seraj J, Weaver R, Lemech C, Todaro TG, Pant S, Arkenau HT.

Cancer Chemother Pharmacol. 2016 Jun;77(6):1275-83. doi: 10.1007/s00280-016-3031-9. Epub 2016 May 5.

2.

Human mass balance study of TAS-102 using (14)C analyzed by accelerator mass spectrometry.

Lee JJ, Seraj J, Yoshida K, Mizuguchi H, Strychor S, Fiejdasz J, Faulkner T, Parise RA, Fawcett P, Pollice L, Mason S, Hague J, Croft M, Nugteren J, Tedder C, Sun W, Chu E, Beumer JH.

Cancer Chemother Pharmacol. 2016 Mar;77(3):515-26. doi: 10.1007/s00280-016-2965-2. Epub 2016 Jan 19.

3.

TP53 gene expression in HPV-positive oral tongue SCC and its correlation with nodal metastasis.

Seraj JM, Yazdani N, Ashtiani ZO, Seraj SM, Hasheminasab SM, Memar B, Mirashrafi F, Borghei H, Yazdani J, Mostaan LV.

Pathol Res Pract. 2011 Dec 15;207(12):758-61. doi: 10.1016/j.prp.2011.09.013. Epub 2011 Nov 4.

PMID:
22055991
4.

4-Aryl-5-cyano-2-aminopyrimidines as VEGF-R2 inhibitors: synthesis and biological evaluation.

Hughes TV, Emanuel SL, Beck AK, Wetter SK, Connolly PJ, Karnachi P, Reuman M, Seraj J, Fuentes-Pesquera AR, Gruninger RH, Middleton SA, Lin R, Davis JM, Moffat DF.

Bioorg Med Chem Lett. 2007 Jun 15;17(12):3266-70. Epub 2007 Apr 10.

PMID:
17481894
5.

Synthesis and biological study of 2-amino-4-aryl-5-chloropyrimidine analogues as inhibitors of VEGFR-2 and cyclin dependent kinase 1 (CDK1).

Huang S, Li R, Connolly PJ, Emanuel S, Fuentes-Pesquera A, Adams M, Gruninger RH, Seraj J, Middleton SA, Davis JM, Moffat DF.

Bioorg Med Chem Lett. 2007 Apr 15;17(8):2179-83. Epub 2007 Feb 2.

PMID:
17317182
6.

Relationship between serum butyrylcholinesterase and the metabolic syndrome.

Randell EW, Mathews MS, Zhang H, Seraj JS, Sun G.

Clin Biochem. 2005 Sep;38(9):799-805.

PMID:
15907830
7.

Requirement of activated Cdc42-associated kinase for survival of v-Ras-transformed mammalian cells.

Nur-E-Kamal A, Zhang A, Keenan SM, Wang XI, Seraj J, Satoh T, Meiners S, Welsh WJ.

Mol Cancer Res. 2005 May;3(5):297-305.

8.

Profiling the evolution of human metastatic bladder cancer.

Nicholson BE, Frierson HF, Conaway MR, Seraj JM, Harding MA, Hampton GM, Theodorescu D.

Cancer Res. 2004 Nov 1;64(21):7813-21.

9.

Manipulation of gene expression by an ecdysone-inducible gene switch in tumor xenografts.

Karns LR, Kisielewski A, Gulding KM, Seraj JM, Theodorescu D.

BMC Biotechnol. 2001;1:11. Epub 2001 Dec 18.

Supplemental Content

Support Center